

Regulatory information - Paris, 31 August 2017

### First-half 2017 consolidated financial statements

**Operating income: 4.7% of revenues**

**Net income: 3.8% of revenues**

**On 31 July 2017, the Group finalised the acquisition of 100% of the share capital of the Swedish company Exensor, an international leader in the supply of sensors and protection networks for sensitive areas and infrastructures.**

As a member of the Group, Exensor will strengthen Bertin Technologies' presence in the instrumentation and surveillance market for defense and security applications.

**On 31 August 2017, Bertin Pharma, a subsidiary of Bertin Technologies, sold its pharmaceutical and biotech services operations to two French specialist companies in that field.**

Bertin Pharma has retained the operations relating to the supply of bioanalysis tools and biological reagents for Defense and Life Sciences.

#### Key figures for the first half of 2017:

<b>Order intake:</b>	<b>Revenues:</b>	<b>Operating income:</b>	<b>Net income:</b>
€387.8 million	€266.4 million	€12.6 million	€10.1 million

CNIM's Supervisory Board met on 31 August 2017 to examine the first-half 2017 consolidated financial statements as approved by the Management Board.

Operating income for the period was €12.6 million, representing 4.7% of revenues. The Group's first-half year EBITDA was €20.7 million, representing 7.8% of revenues.

Net income was €10.1 million.

Consolidated financial statements (in € millions)	1st half 2017	1st half 2016
Revenues	266.4	249.2
Operating income	12.6	14.0
Income before tax	13.9	15.4
<b>Net income</b>		
Continuing operations	10.1	12.9
Discontinued operations	-	1.8
<b>Net income attributable to owners of the parent</b>	<b>10.1</b>	<b>14.7</b>

*The consolidated financial statements for the period from 1 January 2017 to 30 June 2017 have been subject to a limited review by our statutory auditors, who have issued their report on the first-half financial information.*

## Order intake and backlog at 30 June 2017

(in € millions)	Order intake 1st half 2017	Order intake 1st half 2016	Backlog at 30/06/2017
Environment	303.4	182.6	791.9
Innovation & Systems	84.4	57.4	235.0
<b>Group total</b>	<b>387.8</b>	<b>240.0</b>	<b>1,026.9</b>

Order intake for the first half of 2017 was €387.8 million, as against €240.0 million in the first half of 2016 and €350.6 million in the first half of 2015. The backlog was 13.4% higher than the one achieved at 31 December 2016.

## Cash position

The Group's cash position, net of all debt, stood at €122.6 million at 30 June 2017.

## Outlook for 2017

With the acquisition of Exensor and the sale of all of Bertin Pharma's services operations, and following on from the acquisition of Saphymo in 2015, the Group is continuing in 2017 to strengthen Bertin Technologies' core business: instrumentation and surveillance systems for defense and security applications.

From a wider perspective, these transactions will enable the Innovations & Systems Sector to concentrate on activities with a significant technological and industrial focus, and for which the Group is the market leader, both in France and abroad.

As regards the Environment Sector, CNIM, the European market leader, is pursuing its strategy of expanding its business into new geographic regions with favourable prospects in 2017 and beyond.

## About CNIM Group

CNIM Group develops, designs and produces turnkey industrial solutions with high technological content and provides expertise, services and operations in the areas of the environment, energy, defense and industry.

Contact: [info-communication@cnim.com](mailto:info-communication@cnim.com) Financial calendar available at [www.cnim.com](http://www.cnim.com)